ClinicalTrials.gg
CompletedNCT03415087Updated Jan 30, 2018

Sequential Intrathecal Injection of Fentanyl and Hyperbaric Bupivacaine

An interventional study of sequential intrathecal injection and hyperbaric bupivacaine in Elective Caesarean Section, sponsored by Ain Shams University. Completed. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-01-30.

Sponsored by Ain Shams University · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Jan 2016, registered Dec 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

56 Parturients, aged 18-40 year, undergoing elective CS were randomly assigned to receive sequential intrathecal injection of fentanyl and hyperbaric bupivacaine at the same rate (normal sequential) NS or a rapid intrathecal injection of fentanyl followed by slow injection of hyperbaric bupivacaine (rapid sequential) RS. Time of first rescue analgesia, Dose of rescue analgesics, degree of postoperative pain, incidence of hypotension, hypotension duration, ephedrine dose, spinal anaesthesia related complications and failed block were recorded.

Read the detailed description

56 ASA physical status I, II Parturients, aged 18-40 year, undergoing elective CS were randomly assigned to receive sequential intrathecal injection of fentanyl and hyperbaric bupivacaine at the same rate through a 5ml syringe each (NS (normal sequential), n 28) or a rapid intrathecal injection of fentanyl through an insuline syringe followed by slow injection of hyperbaric bupivacaine through a 5ml syringe RS (rapid sequential), n 28). Onset of sensory block (T6 level), highest level of sensory block, time of first rescue analgesia, Dose of rescue analgesics, degree of postoperative pain by VAS 6H postoperative, Onset of motor block (Bromage scale0>3), duration of motor block (return to Bromage 0), incidence of hypotension, hypotension duration, ephedrine dose, spinal anaesthesia related complications as nausea, vomiting, pruritis, shivering and failed block were recorded.

02

Conditions studied

  • Elective Caesarean Section
03

In context

Lead sponsor

Ain Shams University is the lead sponsor of 1,950 studies on the registry; 429 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • , II
  • Parturients aged from 18-40 years old
  • scheduled for elective CS

Exclusion criteria

Exclusion Criteria:

  • parturients with complicated pregnancy as (preeclampsia, pregnancy induced HTN, gestational Diabetes, abnormal placenta (placenta previa), multiple gestation),
  • greater than 35 or less than 22,
  • major systemic disease (cardiac, renal, liver),
  • need for emergency CS,
  • having allergy to drugs used in the study,
  • having for spinal anaesthesia or
  • refused regional anaesthesia
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Active comparator
    sequential intrathecal injection of fentanyl and bupivacaine

    intrathecal injection drug: fentanyl 25 μg (0.5 ml), IV,once drug: hyperbaric bupivacaine 0.5%10 mg IV,once both syringes were injected slowly sequentially

    Procedure: sequential intrathecal injection · Drug: hyperbaric bupivacaine · Drug: fentanyl

  • Experimental
    rapid sequential intrathecal injection of fentanyl and bupiva

    intrathecal injection drug: fentanyl 25 μg (0.5 ml), IV, injected rapidly and mixed by CSF, once drug: hyperbaric bupivacaine 0.5%10 mg IV injected slowly once.

    Procedure: sequential intrathecal injection · Drug: hyperbaric bupivacaine · Drug: fentanyl

Interventions

  • Proceduresequential intrathecal injection

    intrathecal injection of fentanyl and hyperbaric bupivacaine

    Also known as: sequential spinal anaesthesia

  • intrathecal injection of intrathecal bupivacaine

    Also known as: heavy marcaine

  • intrathecal injection of fentanyl

    Also known as: opioid

06

What researchers measure

Primary outcomes

  1. Duration of postoperative analgesia

    technique provides prolonged post operative analgesia

    Time frame: 2-5 hours

Secondary outcomes

  1. incidence of hypotension

    note if hypotension occurs

    Time frame: 30 minutes

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in Jul 2016, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2017
First posted
Jan 30, 2018
StartActual
Jan 1, 2016
Primary completionActual
Jul 1, 2016
CompletionActual
Jul 1, 2016
Last update
Jan 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03415087
Responsible party
Rania Maher Hussien (principle investigator, Ain Shams University) — Principal investigator
First posted
Jan 30, 2018
Start date
Jan 1, 2016
Primary completion
Jul 1, 2016
Completion
Jul 1, 2016
Last update
Jan 30, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Fentanyl

Start the discussion